Pembrolizumab for treatment-refractory metastatic castration-resistant prostate cancer: Multicohort, open-label phase II KEYNOTE-199 study
- Emmanuel S. Antonarakis
- , Josep M. Piulats
- , Marine Gross-Goupil
- , Jeffrey Goh
- , Kristiina Ojamaa
- , Christopher J. Hoimes
- , Ulka Vaishampayan
- , Ranaan Berger
- , Ahmet Sezer
- , Tuomo Alanko
- , Ronald de Wit
- , Chunde Li
- , Aurelius Omlin
- , Giuseppe Procopio
- , Satoshi Fukasawa
- , Ken ichi Tabata
- , Se Hoon Park
- , Susan Feyerabend
- , Charles G. Drake
- , Haiyan Wu
- Johns Hopkins University
- University of Barcelona
- Centre Georges-François Leclerc
- Royal Brisbane and Women's Hospital
- University of Queensland
- East Tallinn Central Hospital
- Case Western Reserve University
- Wayne State University
- Sheba Medical Center at Tel Hashomer
- Baskent University
- Docrates Cancer Center
- Erasmus University Rotterdam
- Karolinska Institutet
- University of Bern
- IRCCS Fondazione Istituto Nazionale per lo studio e la cura dei tumori - Milano
- Chiba Cancer Center
- Kitasato University
- Studienpraxis Urologie
- New York Presbyterian Hospital
- MSD China
- Merck
- Institute of Cancer Research
Research output: Contribution to journal › Article › peer-review
638
Link opens in a new tab
Scopus
citations